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Background: Tumor volume has been considered an important variable in determining the probability of disease
progression in prostatic adenocarcinoma. There have been many studies that have tried to determine an appropriate
method of calculating tumor volume, but no single methodology has been agreed upon. We tested the hypothesis
that the ratio of tumor positive tissue blocks to the total number of blocks submitted (positive-block ratio) can be
used as an independent prognostic indicator for disease recurrence.
Design: We analyzed 504 patients who underwent total radical retropubic prostatectomy between 1990 and
1998. None of the patients had preoperative radiation or androgen-deprivation therapy. Clinical records were
reviewed.
Results: The mean positive-block ratio was 0.44 (median, 0. 43; range, 0.05-1.0). The positive block-ratio was
significantly associated with Gleason score, pathologic stage, surgical margin status, extraprostatic extension,
seminal vesical invasion, lymph node metastasis, perineural invasion, and preoperative serum PSA level (all P <
0.001). Using a multivariate Cox regression model, controlling for pathological stage, Gleason score, and surgical
margin status, positive-block ratio was an independent predictor of PSA recurrence (hazard ratio, 2.4; 95%
confidence interval, 1.1-5.1; P = 0.02). Five-year PSA recurrence-free survival was 67% for those patients
with positive-block ratio 0.43, as compared to 42% those with positive-block ratio > 0.43 (P < 0.001).
Conclusions: Positive-block ratio is an independent predictor of PSA recurrence and we recommend that this
variable be recorded in radical prostatectomy specimens.
Editorial Comment
One of the most controversial aspects of the pathologic assessment of radical prostatectomy specimens is the
measurement of tumor volume (1). No accepted standard exists for reporting cancer volume in prostatectomy
specimens (2). Some institutions have calculated tumor volume accurately using computer-assisted image analysis
systems. Because this method is not feasible for routine clinical practice, other investigators have proposed
alternative simpler means of measuring tumor volume including diameter of largest tumor focus, number of
tumor foci, number of involved blocks, percentage of blocks involved, use of a grid with 3.0 mm squares, or
naked eye examination of the glass slides after the pathologist had circled all microscopically identifiable foci of
carcinoma with a marking pen (the pathologist’s percentage estimate) (3-7). The method for evaluating tumor
extent applied and proposed in the study by Marks et al. is based in the positive-block ratio and is a simple one
and accessible to all general pathologists. Actually is easier than the one we proposed based on a point count
method (8).
Numerous studies have documented that tumor extent, volume and percentage of prostatic tissue involved
by tumor within the prostate gland are important prognostic indicators. Tumor extent has been correlated with
histologic grade, clinicopathologic stage, extraprostatic extension, seminal vesicle invasion, metastasis, tumor
progression, and patient survival rate (6).
Although most authors agree that tumor size (percentage of carcinoma or tumor volume) in patients
with prostate carcinoma should be reported in radical prostatectomies because of its prognostic importance, in
some analyses, tumor size has not been considered to be an independent predictor of tumor recurrence (1,9). In
the study surveyed, Marks et al. have shown that the 5-year biochemical-free progression was 67% for those
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patients with positive-block ratio 0.43, as compared to 42% for those with positive-block ratio > 0.43 (p < 0.001)
and that the positive-block ratio is an independent predictor of biochemical progression.
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Inflammatory myofibroblastic tumor of the urinary bladder is an unusual spindle cell neoplasm that displays
cytologic atypia, infiltrative growth and mitotic activity mimicking malignant tumors, such as leiomyosarcoma,
rhabdomyosarcoma and sarcomatoid carcinoma. The objective of this study was to determine if anaplastic
lymphoma kinase (ALK-1) protein expression detected by immunohistochemistry and ALK rearrangements
detected by fluorescence in situ hybridization (FISH) were useful in distinguishing inflammatory myofibroblastic
tumor from malignant spindle cell tumors of the urinary bladder. In inflammatory myofibroblastic tumor, ALK-
1 expression was identified in 13 of 21 cases (62%) and ALK rearrangements in 14 of 21 cases (67%). All
cases of inflammatory myofibroblastic tumor demonstrating ALK-1 expression, carried ALK rearrangements.
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One case negative for ALK-1 expression exhibited ALK rearrangement. ALK rearrangements were more
common in women (P=0.0032). Leiomyosarcoma, sarcomatoid carcinoma, embryonal rhabdomyosarcoma and
reactive myofibroblastic proliferations were negative for ALK-1 protein and ALK rearrangements.
Immunohistochemistry using markers of muscle, epithelial, neural, and follicular dendritic cell differentiation
showed overlap between inflammatory myofibroblastic tumor with and without ALK gene rearrangements, and
between inflammatory myofibroblastic tumor and spindle cell malignancies. However, coexpression of cytokeratin
and muscle-specific antigens was unique to inflammatory myofibroblastic tumor, observed in approximately
half the tumors. This study indicates that detection of ALK protein and ALK gene rearrangements are useful in
distinguishing inflammatory myofibroblastic tumor from spindle cell malignancies in the urinary bladder.
Additionally, our findings suggest that ALK rearrangement is the primary mechanism for ALK activation and
that inflammatory myofibroblastic tumor likely represents a heterogeneous group of spindle cell proliferations
with the majority associated with ALK translocations, and the remaining associated with other etiologies.
Editorial Comment
Inflammatory myofibroblastic tumor is a rare lesion occurring at a number of anatomic sites, including the
urinary bladder. The vast majority of these tumors behave in a benign fashion, although occasionally tumors can
recur following surgical excision. Due to the fact that displays cytologic atypia, infiltrative growth and mitotic
activity, the tumor mimics aggressive malignant tumors, such as leiomyosarcoma and sarcomatoid carcinoma.
The differential diagnosis is of utmost importance and particularly difficult for the pathologist. The
sarcomatoid variant of urothelial carcinoma is a very aggressive tumor. In a study by Lopez-Beltran et al., 70%
of patients died of cancer at 1 to 48 months (mean 17 months) (1). Leiomyosarcoma is a rare malignant
mesenchymal tumor that arises from urinary bladder smooth muscle and is the most common sarcoma of the
urinary bladder. Although previous reports suggest that 5-year survival after partial or radical cystectomy
approaches 70%, the largest recent study indicates that 70% of patients with leiomyosarcoma developed recurrent
or metastatic disease, resulting in death in nearly half (2).
The study by Sukov et al. emphasizes the importance of immunohistochemistry as a help for the pathologist in
the differential diagnosis of spindle cell lesions of the urinary bladder. In inflammatory myofibroblastic tumor
there is a clonal aberration typically involving chromosome 2p (3). This results in rearrangement of the ALK
gene which codifies a receptor of tyrosine-kinase and hence over-expression of ALK-1 protein which is disclosed
by immunohistochemistry in up of 62% of the cases.
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